Top

Tip

Swipe om te navigeren naar een ander artikel

Gepubliceerd in:

20-02-2020

Predictors of health-related quality of life among military HIV-infected individuals

Auteurs: Leonard Emuren, Seth Welles, Grace Macalino, Alison A. Evans, Marcia Polansky, Anuradha Ganesan, Rhonda E. Colombo, Brian K. Agan, the Infectious Disease Clinical Research Program HIV Working Group

Gepubliceerd in: Quality of Life Research | Uitgave 7/2020

Abstract

Objectives

To determine long-term predictors of health-related quality of life (HRQOL) and evaluate the treatment effect of highly active antiretroviral therapy (HAART) on HRQOL in the US Military HIV Natural History Study (NHS) cohort.

Methods

Participants were a nested cohort of the NHS who responded to the Rand Short Form 36 questionnaire administered from 2006 to 2010. Physical component summary scores (PCS) and mental component summary scores (MCS) were computed using standard algorithms. HAART-status was categorized as non-protease inhibitor-based (NPI-HAART), protease inhibitor-based (PI-HAART), HAART-naïve, or off-HAART. Mixed linear random effects models were used to estimate changes in PCS and MCS over time for treatment and covariates (including CD4 count, HIV viral load, medical and mental comorbidities).

Results

Eight hundred and twelve participants met the inclusion criteria. There was no difference in PCS or MCS between those on PI-HAART compared to NPI-HAART. Significant predictors of PCS were CD4 count < 200 cells/mm³ (β = − 2.90), CD4 count 200–499 cells/mm³ (β = − 0.80), and mental comorbidity (β = − 3.23). Others were medical comorbidity, AIDS-defining illness, being on NPI-HAART, HAART-naïve, age, and rank. Those with medical comorbidities experienced yearly improvement in PCS. Predictors of MCS were CD4 count < 200 cells/mm³ (β = − 2.53), mental comorbidity (β = − 4.58), and being African American (β = 2.59).

Conclusion

HRQOL was significantly affected by low CD4 count, medical and mental comorbidities. Addressing these modifiable factors would be expected to improve the physical and mental HRQOL of the cohort. Our study did not find any treatment benefit of NPI-HAART over PI-HAART on HRQOL in the long term.

vorige artikel Health-related quality of life after sleeve gastrectomy equal to Roux-en-Y gastric bypass patients?

volgende artikel Pain catastrophizing mediates the negative influence of pain and trait-anxiety on health-related quality of life in fibromyalgia

Alleen toegankelijk voor geautoriseerde gebruikers

Wenger, N., & Furberg, C. (1990). Cardiovascular disorders. Quality of life assessment in clinical trials (pp. 335–345). New York: Raven Press.

Emuren, L., Welles, S., Evans, A. A., Polansky, M., Okulicz, J. F., Macalino, G., et al. (2017). Health-related quality of life among military HIV patients on antiretroviral therapy. PLoS ONE, 12(6), e0178953. https://doi.org/10.1371/journal.pone.0178953. CrossRefPubMedPubMedCentral

Liu, C., Ostrow, D., Detels, R., Hu, Z., Johnson, L., Kingsley, L., et al. (2006). Impacts of HIV infection and HAART use on quality of life. Quality of Life Research, 15(6), 941–949. https://doi.org/10.1007/s11136-005-5913-x. CrossRefPubMed

Jin, Y., Liu, Z., Wang, X., Liu, H., Ding, G., Su, Y., et al. (2014). A systematic review of cohort studies of the quality of life in HIV/AIDS patients after antiretroviral therapy. International Journal of STD and AIDS, 25(11), 771–777. https://doi.org/10.1177/0956462414525769. CrossRefPubMed

Rodriguez-Penney, A. T., Iudicello, J. E., Riggs, P. K., Doyle, K., Ellis, R. J., Letendre, S. L., et al. (2013). Co-morbidities in persons infected with HIV: Increased burden with older age and negative effects on health-related quality of life. AIDS Patient Care STDS, 27(1), 5–16. https://doi.org/10.1089/apc.2012.0329. CrossRefPubMedPubMedCentral

Nicholas, P. K., Kirksey, K. M., Corless, I. B., & Kemppainen, J. (2005). Lipodystrophy and quality of life in HIV: Symptom management issues. Applied Nursing Research, 18(1), 55–58. https://doi.org/10.1016/j.apnr.2004.09.012. CrossRefPubMed

Burgoyne, R. W., & Tan, D. H. (2008). Prolongation and quality of life for HIV-infected adults treated with highly active antiretroviral therapy (HAART): A balancing act. Journal of Antimicrobial Chemotherapy, 61(3), 469–473. https://doi.org/10.1093/jac/dkm499. CrossRefPubMed

Protopopescu, C., Marcellin, F., Spire, B., Preau, M., Verdon, R., Peyramond, D., et al. (2007). Health-related quality of life in HIV-1-infected patients on HAART: a five-years longitudinal analysis accounting for dropout in the APROCO-COPILOTE cohort (ANRS CO-8). Quality of Life Research, 16(4), 577–591. https://doi.org/10.1007/s11136-006-9151-7. CrossRefPubMed

Fumaz, C. R., Tuldra, A., Ferrer, M. J., Paredes, R., Bonjoch, A., Jou, T., et al. (2002). Quality of life, emotional status, and adherence of HIV-1-infected patients treated with efavirenz versus protease inhibitor-containing regimens. Journal of Acquired Immune Deficiency Syndromes, 29(3), 244–253. CrossRef

10.

Anis, A. H., Nosyk, B., Sun, H., Guh, D. P., Bansback, N., Li, X., et al. (2009). Quality of life of patients with advanced HIV/AIDS: measuring the impact of both AIDS-defining events and non-AIDS serious adverse events. Journal of Acquired Immune Deficiency Syndromes, 51(5), 631–639. https://doi.org/10.1097/QAI.0b013e3181a4f00d. CrossRefPubMed

11.

Jia, H., Uphold, C. R., Zheng, Y., Wu, S., Chen, G. J., Findley, K., et al. (2007). A further investigation of health-related quality of life over time among men with HIV infection in the HAART era. Quality of Life Research, 16(6), 961–968. https://doi.org/10.1007/s11136-007-9214-4. CrossRefPubMed

12.

Jia, H., Uphold, C. R., Wu, S., Chen, G. J., & Duncan, P. W. (2005). Predictors of changes in health-related quality of life among men with HIV infection in the HAART era. AIDS Patient Care STDS, 19(6), 395–405. https://doi.org/10.1089/apc.2005.19.395. CrossRefPubMed

13.

Liu, C., Johnson, L., Ostrow, D., Silvestre, A., Visscher, B., & Jacobson, L. P. (2006). Predictors for lower quality of life in the HAART era among HIV-infected men. Journal of Acquired Immune Deficiency Syndromes, 42(4), 470–477. https://doi.org/10.1097/01.qai.0000225730.79610.61. CrossRefPubMed

14.

Chun, H. M., Roediger, M. P., Hullsiek, K. H., Thio, C. L., Agan, B. K., Bradley, W. P., et al. (2012). Hepatitis B virus coinfection negatively impacts HIV outcomes in HIV seroconverters. Journal of Infectious Diseases, 205(2), 185–193. https://doi.org/10.1093/infdis/jir720. CrossRefPubMed

15.

Chun, H. M., Fieberg, A. M., Hullsiek, K. H., Lifson, A. R., Crum-Cianflone, N. F., Weintrob, A. C., et al. (2010). Epidemiology of Hepatitis B virus infection in a US cohort of HIV-infected individuals during the past 20 years. Clinical Infectious Diseases, 50(3), 426–436. https://doi.org/10.1086/649885. CrossRefPubMedPubMedCentral

16.

Pelak, K., Goldstein, D. B., Walley, N. M., Fellay, J., Ge, D., Shianna, K. V., et al. (2010). Host determinants of HIV-1 control in African Americans. Journal of Infectious Diseases, 201(8), 1141–1149. https://doi.org/10.1086/651382. CrossRefPubMed

17.

Spaulding, A. B., Lifson, A. R., Iverson, E. R., Ganesan, A., Landrum, M. L., Weintrob, A. C., et al. (2012). Gonorrhoea or chlamydia in a US military HIV-positive cohort. Sexually Transmitted Infections, 88(4), 266–271. https://doi.org/10.1136/sextrans-2011-050173. CrossRefPubMed

18.

RAND. Scoring instructions for the 36-item short form survey (SF-36). Retrieved May 05, 2013, from https://www.rand.org/health/surveys_tools/mos/mos_core_36item_scoring.html.

19.

Hays, R.D. SAS code for scoring 36-item health survey 1.0. Retrieved May 9, 2014, from https://gim.med.ucla.edu/FacultyPages/Hays/utils/SF36/sf36.sas.

20.

Hopman, W. M., Berger, C., Joseph, L., Towheed, T., Prior, J. C., Anastassiades, T., et al. (2009). Health-related quality of life in Canadian adolescents and young adults: Normative data using the SF-36. Canadian Journal of Public Health, 100(6), 449–452. CrossRef

21.

Fitzmaurice, G. M., Laird, N. M., & Ware, J. H. (2011). Applied longitudinal analysis (Second ed., Wiley Series in Probability and Statistics). New Jersey: Wiley. CrossRef

22.

Gakhar, H., Kamali, A., & Holodniy, M. (2013). Health-related quality of life assessment after antiretroviral therapy: a review of the literature. Drugs, 73(7), 651–672. https://doi.org/10.1007/s40265-013-0040-4. CrossRefPubMedPubMedCentral

23.

Degroote, S., Vogelaers, D., & Vandijck, D. M. (2014). What determines health-related quality of life among people living with HIV: an updated review of the literature. Archives of Public Health, 72(1), 40. https://doi.org/10.1186/2049-3258-72-40. CrossRefPubMedPubMedCentral

24.

Doyle, K., Weber, E., Atkinson, J. H., Grant, I., & Woods, S. P. (2012). Aging, prospective memory, and health-related quality of life in HIV infection. AIDS and Behavior, 16(8), 2309–2318. https://doi.org/10.1007/s10461-011-0121-x. CrossRefPubMedPubMedCentral

25.

Effros, R. B., Fletcher, C. V., Gebo, K., Halter, J. B., Hazzard, W. R., Horne, F. M., et al. (2008). Aging and infectious diseases: workshop on HIV infection and aging: what is known and future research directions. Clinical Infectious Diseases, 47(4), 542–553. https://doi.org/10.1086/590150. CrossRefPubMedPubMedCentral

26.

Corless, I. B., Kirksey, K. M., Kemppainen, J., Nicholas, P. K., McGibbon, C., Davis, S. M., et al. (2005). Lipodystrophy-associated symptoms and medication adherence in HIV/AIDS. AIDS Patient Care STDS, 19(9), 577–586. https://doi.org/10.1089/apc.2005.19.577. CrossRefPubMed

27.

Potard, V., Chassany, O., Lavignon, M., Costagliola, D., & Spire, B. (2010). Better health-related quality of life after switching from a virologically effective regimen to a regimen containing efavirenz or nevirapine. AIDS Care, 22(1), 54–61. https://doi.org/10.1080/09540120903033250. CrossRefPubMed

28.

Campo, R. E., Cohen, C., Grimm, K., Shangguan, T., Maa, J., & Seekins, D. (2010). Switch from protease inhibitor- to efavirenz-based antiretroviral therapy improves quality of life, treatment satisfaction and adherence with low rates of virological failure in virologically suppressed patients. International Journal of STD and AIDS, 21(3), 166–171. https://doi.org/10.1258/ijsa.2009.008487. CrossRefPubMed

29.

Crum-Cianflone, N. F., Grandits, G., Echols, S., Ganesan, A., Landrum, M., Weintrob, A., et al. (2010). Trends and causes of hospitalizations among HIV-infected persons during the late HAART era: what is the impact of CD4 counts and HAART use? Journal of Acquired Immune Deficiency Syndromes, 54(3), 248–257. CrossRef

30.

Pogany, K., van Valkengoed, I. G., Prins, J. M., Nieuwkerk, P. T., van der Ende, I., Kauffmann, R. H., et al. (2007). Effects of active treatment discontinuation in patients with a CD4+ T-cell nadir greater than 350 cells/mm3: 48-week Treatment Interruption in Early Starters Netherlands Study (TRIESTAN). Journal of Acquired Immune Deficiency Syndromes, 44(4), 395–400. https://doi.org/10.1097/QAI.0b013e31802f83bc. CrossRefPubMed

31.

Joyce, V. R., Barnett, P. G., Chow, A., Bayoumi, A. M., Griffin, S. C., Sun, H., et al. (2012). Effect of treatment interruption and intensification of antiretroviral therapy on health-related quality of life in patients with advanced HIV: A randomized, controlled trial. Medical Decision Making, 32(1), 70–82. https://doi.org/10.1177/0272989x10397615. CrossRefPubMed

32.

Burman, W. J., Grund, B., Roediger, M. P., Friedland, G., Darbyshire, J., & Wu, A. W. (2008). The impact of episodic CD4 cell count-guided antiretroviral therapy on quality of life. Journal of Acquired Immune Deficiency Syndromes, 47(2), 185–193. https://doi.org/10.1097/QAI.0b013e31815acaa4. CrossRefPubMed

33.

Walker, A. M. (1996). Confounding by indication. Epidemiology, 7(4), 335–336. PubMed

34.

Panel on Antiretroviral Guidelines for Adults and Adolescents. (Updated February 2013. Accessed April 7, 2019). Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. https://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf.

35.

World Health Organization (WHO) (September 2015.). Guidelines on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. Retrieved 7 April, 2019, from https://www.who.int/hiv/pub/guidelines/earlyreleasr-arv/en.

36.

Rodger, A. J., & Sabin, C. A. (2016). How have guidelines on when to start antiretroviral therapy affected survival of people living with HIV infection? Current Opinion in HIV and AIDS, 11(5), 487–491. https://doi.org/10.1097/coh.0000000000000307. CrossRefPubMed

37.

Eholié, S. P., Badje, A., Kouame, G. M., Ntakpe, J. B., Moh, R., Danel, C., et al. (2016). Antiretroviral treatment regardless of CD4 count: The universal answer to a contextual question. AIDS Research and Therapy, 13, 27. https://doi.org/10.1186/s12981-016-0111-1. CrossRefPubMedPubMedCentral

Titel: Predictors of health-related quality of life among military HIV-infected individuals
Auteurs: Leonard Emuren
Seth Welles
Grace Macalino
Alison A. Evans
Marcia Polansky
Anuradha Ganesan
Rhonda E. Colombo
Brian K. Agan
the Infectious Disease Clinical Research Program HIV Working Group
Publicatiedatum: 20-02-2020
Uitgeverij: Springer International Publishing
Gepubliceerd in: Quality of Life Research / Uitgave 7/2020
Print ISSN: 0962-9343
Elektronisch ISSN: 1573-2649
DOI: https://doi.org/10.1007/s11136-020-02441-5

Bohn Stafleu van Loghum

Tip

Swipe om te navigeren naar een ander artikel

Deel dit onderdeel of sectie (kopieer de link)

Abstract

Objectives

Methods

Results

Conclusion

Log in om toegang te krijgen

Andere artikelen Uitgave 7/2020

A moderated mediation model of perceived stress, negative emotions and mindfulness on fertility quality of life in women with recurrent pregnancy loss

Self-esteem in patients with inflammatory bowel disease

Evaluation of quality of life and its influencing factors after transplantation of leukemia patients based on SF-36 score: a cohort study

Quality of life in people with epidermolysis bullosa: a systematic review

FDA review summary of patient-reported outcome results for ibrutinib in the treatment of chronic graft versus host disease

Psychometric properties of a single-item visual analog scale measuring goals of care in patients with advanced cancer